Annual Report 2022
Section of Cancer Genomics Repository
Tomohisa Sudo, Azusa Takeuchi, Jun Oikawa, Tsuyuka Otsuki, Takehito Saito
Introduction
Our section was established in June 2018 as one of the sections of the Center for Cancer Genomics and Advanced Therapeutics (C-CAT).
The Team and What We Do
The Section of Cancer Genomics Repository (CGR) collects clinical information and genomic data from the cancer genomic medicine (CGM) hospitals (designated core, core and affiliated hospitals), and clinical laboratories for Comprehensive Genomic Profiling (CGP) test. The information and data are registered in the C-CAT Repository database and used by the CGM hospitals for the clinical purposes of the present and future patients, including the production of the C-CAT findings to list the current clinical trials, which might be available domestically. The C-CAT Repository data are also offered widely to the academia and industries under a fair and transparent protocol to be used for the secondary or research and development purposes. By March 2023, more than 50,000 patients have given informed consents for the registration of their information and data to the C-CAT Repository.
CGR serves as a secretariat for the Registration of the Patient information Working Group (RPWG) of the Liaison Council of the Cancer Genomic Medicine Hospitals, which specifies the clinical information to be aggregated to C-CAT. In 2022, the list of the clinical information has been updated for solid tumors, and a new list for the hematological malignancies was established.
Education
CGR has offered several explanatory meetings for the CGM hospitals, as well as the helpdesk support for their questions and request. On-the-job training is the mainstay of the training for new staff in CGR.
Future Prospects
CGR will keep supporting the CGP testing under the National Health Insurance system in Japan. In particular, CGR will continue to maintain and improve the C-CAT repository system, so that the precious CGM real-world data can be used efficiently and effectively for both the clinical (primary) and research & development (secondary) purposes.